This website is intended for US Healthcare Professionals.

ESMO-BC 2024

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast Cancer: Updated Phase 1b Cohort Results
EP Hamilton et al.
Poster
TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast Cancer
ML Telli et al.

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.